HTG Molecular Diagnostics Inc (NASDAQ:HTGM)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Thursday. They presently have a $5.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 54.80% from the stock’s previous close.
Several other research analysts have also issued reports on the company. Rodman & Renshaw started coverage on HTG Molecular Diagnostics in a research report on Monday, August 22nd. They set a “buy” rating and a $5.00 target price on the stock. Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $5.25.
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded up 4.19% during mid-day trading on Thursday, reaching $3.23. The company had a trading volume of 7,105,654 shares. The company’s market capitalization is $22.77 million. HTG Molecular Diagnostics has a 52 week low of $2.03 and a 52 week high of $6.22. The stock has a 50 day moving average of $2.46 and a 200-day moving average of $2.65.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its earnings results on Tuesday, August 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.03. On average, analysts expect that HTG Molecular Diagnostics will post ($3.58) earnings per share for the current fiscal year.
About HTG Molecular Diagnostics